Carryn M. Anderson, MD, on Head and Neck Cancer: New Data on Avasopasem Manganese for Oral Mucositis

2022 ASCO Annual Meeting


Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses phase III results of the ROMAN trial of avasopasem manganese for patients with severe oral mucositis who are receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer. Compared with placebo, avasopasem manganese improved severe oral mucositis (Abstract 6005).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So I'm excited today to report on the results of the ROMAN trial, which is a phase three randomized trial investigating the role of avasopasem manganese in decreasing severe oral mucositis in head and neck cancer patients receiving concurrent IMRT and cisplatin. So let's talk a little bit about background as to why this clinical trial is so important. Our patients who are receiving concurrent IMRT and cisplatin very commonly suffer from the awful side effect of oral mucositis. It causes severe pain in our patients. They often need high doses of narcotics. They may end up being hospitalized because of the severity of the condition and may end up with treatment breaks and also commonly need feeding tube. The oral mucositis grading system that is utilized in the ROMAN trial is the WHO grading system, and this uses a combined physical exam finding of oral mucositis ulcers in the mouth as well as the impact of those ulcers on a patient's diet. So severe oral mucositis is defined as grade three and four, with three meaning that the ulcers are so bad that patients can no longer take solid diet by mouth and are on liquids only, whereas grade four mucositis means they are now feeding tube dependent. We do not have any FDA approved drugs to mitigate this severe side effect. So enter avasopasem manganese. This is an enzyme that rapidly converts radiation-induced superoxide to hydrogen peroxide. And that is important because superoxide is what causes the downstream cascade of events that results in the development of oral mucositis. Now it has been shown in several basic science experiments as well as, now, several clinical trials that the mechanism of this drug does not spare tumor cells from the damaging effects of radiation, but it does mitigate the side effects to normal cells. So this drug has been tested in a randomized phase two placebo-controlled trial, with two doses of the drug compared against placebo. And it's statistically significantly reduced the duration of severe oral mucositis and the incidence, as well as the severity. Importantly, one- and two-year outcomes were maintained, and the drug did not impact tumor control. So the higher dose of the drug, which was more effective in mitigating severe oral mucositis, was brought forth for phase three testing, and that is what we are reporting today. The ROMAN trial included oral cavity and oral pharynx patients who were receiving IMRT with concurrent cisplatin. The drug was given as a 60-minute IV infusion prior to each radiation fraction, ending 60 minutes prior to the administration of the radiation. Patients were stratified by their surgical status and cisplatin dose schedule, and 455 patients were enrolled. The data presented today is on the intention to treat analysis patients of 407 patients. And importantly, the primary endpoint was met. Ava decreased statistically significantly and clinically meaningfully the incidence of severe oral mucositis at the end of IMRT from 64% down to 54% at a P value of 0.045. Also very importantly, the secondary endpoint of duration of severe oral mucositis, which is a very clinically relevant endpoint, was statistically and impressively reduced by 56% from 18 days on the placebo arm down to only eight days in the Ava arm. The incidence of grade four oral mucositis and the duration of grade four mucositis was also nominally reduced but did not quite meet statistical significance. And this drug did delay the onset of severe oral mucositis from 38 days in the placebo arm to 49 days in the Ava arm. The safety profile of this drug was excellent. Patients experienced the side effects already expected for radiation with concurrent cisplatin. There was a slight increase in nausea and vomiting grade one, mild and limited, in the Ava arm. This is a known side effect of this medicine, but that did not translate to an increase in grade three nausea or vomiting. So we're excited to present today that this is a positive trial. The primary endpoint of severe oral mucositis incidents was statistically and clinically meaningfully reduced. The duration of severe oral mucositis was also statistically significantly and clinically meaningfully reduced in this patient population. We did see nominal decreases in grade four mucositis and a delay in onset of severe oral mucositis. We are excited to follow the tumor outcomes on these patients to report on those at one and two years. The drug is being offered to the FDA by the company, and we hope to hear more about that later this year. And we're also exploring some other endpoints, for example, impact on healthcare utilization and impact of the drug on things like cisplatin-induced kidney injury.

Related Videos

Breast Cancer

Richard Finn, MD, on Advanced Breast Cancer: New Data on Palbociclib Plus Letrozole From PALOMA-2

Richard Finn, MD, of the Geffen School of Medicine at UCLA and the Jonsson Comprehensive Cancer Center, discusses analyses from the PALOMA-2 trial on overall survival with first-line palbociclib plus letrozole vs placebo plus letrozole in women with ER-positive/HER2-negative advanced breast cancer. The study met its primary endpoint of improving progression-free survival but not the secondary endpoint of overall survival. Although patients receiving palbociclib plus letrozole had numerically longer overall survival than those receiving placebo plus letrozole, the results were not statistically significant (Abstract LBA1003).


Courtney D. DiNardo, MD, MSCE, and Stéphane de Botton, MD, PhD, on AML: New Data on IDH2-Mutant Alleles, Enasidenib, and Conventional Care

Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Stéphane de Botton, MD, PhD, of Institut Gustave Roussy, discuss phase III findings from the IDHENTIFY trial, which showed that mutational burden and co-mutational profiles differed between patients with relapsed or refractory acute myeloid leukemia that exhibited IDH2-R140 and IDH2-R172 mutations. Enasidenib improved survival outcomes for patients with IDH2-R172 mutations: median overall survival and 1-year survival rates were approximately double those in the conventional care arm (Abstract 7005).

Lung Cancer

Rami Manochakian, MD, on NSCLC: Clinical Implications of Findings on Nivolumab Plus Chemotherapy

Rami Manochakian, MD, of Mayo Clinic Florida, discusses the phase II findings of the NADIM II trial, which confirmed that, in terms of pathologic complete response as well as the feasibility of surgery, combining nivolumab and chemotherapy was superior to chemotherapy alone as a neoadjuvant treatment for locally advanced, resectable stage IIIA non–small cell lung cancer (Abstract 8501).


Jenny S. Guadamuz, PhD, on Racial and Socioeconomic Disparities in Telemedicine Use Among U.S. Patients With Cancer During the COVID-19 Pandemic

Jenny S. Guadamuz, PhD, of Flatiron Health, discusses the use of telemedicine services in community oncology clinics for patients initiating treatments for 21 common cancers during the COVID-19 pandemic. Black, uninsured, non-urban, and less affluent patients were less likely to use telemedicine services. Although telemedicine may expand access to specialty care, the proliferation of these services may widen cancer care disparities if equitable access to these services is not ensured, according to Dr. Guadamuz (Abstract 6511).

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).